A Year of Partnership and Progress
Looking back at 2025, we find ourselves reflecting not just on the milestones we’ve marked, but on the evolving landscape of our industry. This year has been defined by complexity and opportunity in equal measure. For the biotech community, the challenge has remained consistent: how to navigate the intricate path from a promising molecule to a tangible patient benefit.
At TherapeutAix, this year has been a testament to one of our core beliefs: successful drug discovery requires not just high-level thinking, but hands-on doing.
The Conversations We Shared
If you’ve been following our “Insights” this year, you’ll know that 2025 was a year of deep dives into specific therapeutic challenges.
We spent significant time analyzing the shifting sands of Idiopathic Pulmonary Fibrosis (IPF). Our analysis of the ERS Congress in Amsterdam highlighted a sector in transition, balancing the hope of new mechanisms with the rigorous demands of clinical translation. We explored the implications of the nerandomilast data and asked critical questions about the future of inhaled therapies in fibrotic disease.
Beyond respiratory, we were proud to contribute to the vital conversation on Women’s Health, co-chairing sessions at the SMR meeting in June to help elevate underserved areas of research. And, on a more personal note, we were pleased and excited to support Action Medical Research through the BiotechBikers “Catalyst” charity ride, a reminder that our work is ultimately about improving lives.
Behind the Scenes: The Work
While our blog reflects our thinking, the true measure of our year lies in the work we delivered alongside our partners.
In 2025, we reinforced our position as more than just external advisors. We operated as embedded team members, integrating directly into our clients’ R&D functions. This “Thinking and Doing” model allowed us to move seamlessly from designing high-level strategic roadmaps for early-stage biotechs to executing the operational plans required to bring them to life.
We supported multiple partners (pharma, CROs, investors and charities) through rigorous technical and commercial due diligence, providing the objective scrutiny needed to validate assets for investors and potential partners. In a year where capital efficiency was paramount, helping our clients make the right “go/no-go” decisions was more critical than ever.
A 2025 Highlight: Data, Publications, and Funding
One particular success story stands out this year as a perfect case study of the TherapeutAix approach.
We partnered with a client who possessed a promising asset but needed to translate their raw scientific potential into a compelling narrative for investors. We didn’t just advise on the strategy; we provided hands-on support with the analysis and publication of their results.
By helping them structure and deliver a robust data package, we ensured their science was communicated with clarity and authority. We are incredibly proud to report that this work directly supported the client in securing significant new funding. It is a powerful reminder that in biotech, robust data, when effectively operationalized and communicated, is the currency of success.
Looking Ahead to 2026
As we begin the new year, we remain optimistic about the innovation we see across the industry. The hurdles in drug discovery aren’t going away, but neither is our commitment to helping you clear them.
Whether you need a strategic roadmap to define your direction or an operational partner to help you walk the path, TherapeutAix is ready to join your team.
Here’s to a breakthrough 2026!
